BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
Anthony Gonçalvès, Marine Gilabert, Éric François et al. · Annals of Oncology · 2012
Cited by 225 works. doi:10.1093/annonc/mds135 Open-access PDF
Authors
- Anthony Gonçalvès
- Marine Gilabert
- Éric François
- Laëtitia Dahan
- Hervé Perrier
- R. Lamy
- Daniel Ré
- Remi Largillier
- Mohamed Gasmi
- Xavier Tchiknavorian
- Benjamin Esterni
- Dominique Genre
- Laurence Moureau-Zabotto
- Marc F. Giovannini
- J.F. Seitz
- Jean‐Robert Delpéro
- Olivıer Turrini
- Patrice Viens
- Jean‐Luc Raoul
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Pancreatic Cancer
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- Pancreatic Cancer